Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of GW003 in healthy subjects
NCT02643901Phase 1Completed
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- Sep 2015
- Primary completion
- Oct 2016
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of rHSA-GCSF in chemotherapy-induced neutropenia (CIN) (5 arms), sponsored by Jiangsu T-mab Biopharma Co., Ltd. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. Started Sep 2015; status: completed.
02
Drugs
rHSA-GCSF
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT02643901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643901.